Back to FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

$FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma - FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) cover$

FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Tue Sep 26 2023

Get Free Podcast Summaries in Your Inbox

Subscribe to your favorite podcasts and get free AI summaries within minutes of release.

Pick Your Shows

Browse trending podcasts or search for your favorites

Subscribe Free

One click to follow any show — always free, no credit card

Get Instant Summaries

Free AI summaries delivered by email within minutes of release

Free forever · No credit card · Unsubscribe anytime

Loading summary...

Never miss an episode of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.). Subscribe for free →

No transcript available.